The Food and Drug Administration (FDA) has approved Nubeqa® (darolutamide), an androgen receptor inhibitor, in combination with docetaxel for the treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC).

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 ARASENS trial (ClinicalTrials.gov Identifier: NCT02799602). Patients (N=1306) were randomly assigned 1:1 to receive darolutamide 600mg twice a day or placebo, in combination with docetaxel. All patients received a gonadotropin-releasing hormone analog concurrently or had a bilateral orchiectomy. The primary endpoint was overall survival (OS).

Results showed a statistically significant improvement in OS with darolutamide plus docetaxel compared with placebo plus docetaxel (hazard ratio [HR], 0.68; 95% CI, 0.57-0.80; P <.0001). Median OS was not reached in the darolutamide arm and was 48.9 months (95% CI, 44.4-not reached) in the placebo arm. Overall survival results were consistent across stratified subgroups (extent of disease and alkaline phosphatase level).

Continue Reading

Additionally, treatment with darolutamide plus docetaxel resulted in a statistically significant delay in time to pain progression (secondary endpoint; HR 0.79; 95% CI, 0.66-0.95; 1-sided P =.006). 

The most common adverse reactions reported with darolutamide plus docetaxel were constipation, decreased appetite, rash, hemorrhage, increased weight, and hypertension. Anemia, hyperglycemia, decreased lymphocyte count, decreased neutrophil count, increased AST/ALT and hypocalcemia were the most common laboratory test abnormalities.

Nubeqa is also indicated for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

References

  1. US FDA approves additional indication of Nubeqa® (darolutamide) in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). News release. Bayer. Accessed August 8, 2022. https://www.businesswire.com/news/home/20220805005477/en/U.S.-FDA-Approves-Additional-Indication-of-NUBEQA%C2%AE-darolutamide-in-Combination-with-Docetaxel-for-the-Treatment-of-Metastatic-Hormone-Sensitive-Prostate-Cancer-mHSPC
  2. Nubeqa. Package insert. Bayer; 2022. Accessed August 8, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212099s002lbl.pdf

This article originally appeared on MPR

Topics:

Medications Oncology Prostate And Other Male Cancers Prostate Cancer